Overexpression of cyclooxygenase-2 in multiple myeloma

Basit Öğe Kaydı
dc.authoridCETIN, Mustafa/0000-0003-4512-1124
dc.authoridDeniz, Kemal/0000-0001-7749-2152
dc.authoridOzturk, Ahmet/0000-0002-7130-5624
dc.authoridAltuntas, Fevzi/0000-0001-6872-3780
dc.authorwosidCETIN, Mustafa/B-3607-2015
dc.authorwosidTurgut, Burhan/A-2517-2016
dc.authorwosidCamci, Celaletdin/AAD-1910-2019
dc.authorwosidDeniz, Kemal/Q-3486-2019
dc.authorwosidOzturk, Ahmet/M-6564-2014
dc.authorwosidSari, İbrahim/A-5771-2018
dc.authorwosidAltuntas, Fevzi/E-8945-2015
dc.contributor.authorCetin, M
dc.contributor.authorBuyukberber, S
dc.contributor.authorDemir, M
dc.contributor.authorSari, I
dc.contributor.authorSari, I
dc.contributor.authorDeniz, K
dc.contributor.authorEser, B
dc.date.accessioned2024-06-12T10:58:51Z
dc.date.available2024-06-12T10:58:51Z
dc.date.issued2005
dc.departmentTrakya Üniversitesien_US
dc.description.abstractCyclooxygenases (COX) are key enzymes in the conversion of arachidonic acid to prostaglandins. Several studies have shown a relation between angiogenesis and COX-2 expression. Elevated expression of cyclooxygenase-2 (COX-2), however, has not been reported in multiple myeloma (MM) in the literature. The aim of this study is to investigate COX-2 expression in MM as well as its correlation with prognostic factors and estimated survival rates. Immunohistochemical staining of the paraffin-embedded bone marrow biopsy tissues (n = 51) was performed using isoform-specific COX-2 polyclonal antisera (Santa Cruz Biotechnology, Santa Cruz, CA). Results were correlated with recognized clinical parameters, which were retrospectively obtained from patients'files. There were 15,19, and 17 bone marrow biopsy specimens with negative, weak-moderate, and strong COX-2 immunostaining, respectively. According to univariate analysis, beta 2-microglobulin, age, stage, COX-2 expression, and serum lactate dehydrogenase levels were significant prognostic factors for survival in patients with multiple myeloma. COX-2 expression, age, and serum lactate dehydrogenase levels (greater than 1x normal level) were significant prognostic factors by multivariate analysis. Kaplan-Meier overall survival estimate of those patients with negative or weak-moderate COX-2 immunoreactivity in myeloma cells was significantly better than that of patients with strong COX-2 immunoreactivity (log-rank X-2 = 21,43, P < 0.001). COX-2 overexpression was associated with reduced estimated survival. Poor prognostic factors such as LDH, age, and beta 2-microglobulin were also correlated with COX-2 expression. Potent, specific COX-2 inhibitors showing evident antiangiogenic and antitumor effects on cancers could provide new therapeutic strategies in the treatment of MM.en_US
dc.identifier.doi10.1002/ajh.20460
dc.identifier.endpage173en_US
dc.identifier.issn0361-8609
dc.identifier.issue3en_US
dc.identifier.pmid16247750en_US
dc.identifier.scopus2-s2.0-27644525342en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage169en_US
dc.identifier.urihttps://doi.org/10.1002/ajh.20460
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20200
dc.identifier.volume80en_US
dc.identifier.wosWOS:000233060000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofAmerican Journal Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOX-2 Expressionen_US
dc.subjectMultiple Myelomaen_US
dc.subjectAnglogenesisen_US
dc.subjectEstimated Survivalen_US
dc.titleOverexpression of cyclooxygenase-2 in multiple myelomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu